Plasma Peptidome as a Source of Biomarkers for Diagnosis of Cholangiocarcinoma

Kotawong, Kanawut; Thitapakorn, Veerachai; Roytrakul, Sittiruk; Phaonakrop, Narumon; Viyanant, Vithoon; Na‐Bangchang, Kesara

doi:10.7314/apjcp.2016.17.3.1163

Cited by 3 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High CK2β staining correlates with lower patient survival, and it is an independent prognostic factor in CCA [ 97 ]. In addition, CK2α was specifically detected in plasma of CCA patients suggesting that CK2α is a potential biomarker for CCA diagnosis [ 98 ].…”

Section: Discussionmentioning

confidence: 99%

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

et al. 2017

View full text Add to dashboard Cite

CK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site-specific expression in mice leads to cancer development (e.g., breast, lymphoma) indicating the oncogenic nature of CK2. CK2 is involved in many key aspects of cancer including inhibition of apoptosis, modulation of signaling pathways, DNA damage response, and cell cycle regulation. A number of CK2 inhibitors are now available and have been shown to have activity against various cancers in vitro and in pre-clinical models. Some of these inhibitors are now undergoing exploration in clinical trials as well. In this review, we will examine some of the major cancers in which CK2 inhibition has promise based on in vitro and pre-clinical studies, the proposed cellular and signaling mechanisms of anti-cancer activity by CK2 inhibitors, and the current or recent clinical trials using CK2 inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

et al. 2017

View full text Add to dashboard Cite

show abstract

“…High CK2 expression has been detected in 66% of CCA tissues and was associated with higher TNM stage, histological grade, and poorer overall survival [5] . CK2 has also been detected in the plasma of patients with CCA and can potentially be used as a biomarker for diagnosis [6] . CX-4945 is a potent and highly selective inhibitor of CK2 [7] .…”

Section: Introductionmentioning

confidence: 99%

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma

Zakharia

Miyabe

Wang

et al. 2019

Translational Oncology

View full text Add to dashboard Cite

PURPOSE: We investigated the antitumor effect of the casein kinase II (CK2) inhibitor CX-4945 on cholangiocarcinoma (CCA). METHODS: We assessed the effect of CX-4945 alone and/or in combination with gemcitabine and cisplatin on cell viability, colony formation, and apoptosis of CCA cell lines and on in vivo growth of HuCCT1 xenografts. RESULTS: CX-4945 dose-dependently decreased viability of HuCCT1, EGI-1, and Liv27 and decreased phospho-AKT/total AKT and phospho-PTEN/total PTEN ratios. CX-4945 significantly increased caspase 3/7 activity in a dose- and time-dependent manner. CX-4945 significantly enhanced the effect of gemcitabine or cisplatin on HuCCT1, EGI-1, and Liv27 cells and inhibited the phosphorylation of DNA repairing enzymes XRCC1 and MDC1. Further, CX-4945 alone significantly inhibited growth of HuCCT1 mouse xenograft tumors. Combining CX-4945 with gemcitabine and cisplatin was more potent than CX-4945 alone or gemcitabine/cisplatin. The effect of CX-4945 on cell proliferation, apoptosis, the PI3K/AKT pathway, and DNA repair was confirmed in the mouse xenografts. CONCLUSION: CX-4945 has an antiproliferative effect on CCA and enhances the effect of gemcitabine and cisplatin through its inhibitory effect on the PI3K/AKT pathway and DNA repair.

show abstract

“…Until now, radical surgery remains the only effective strategy for CCA patients. However, due to the silent growth of the cancer and lack of tools for early detection, most CCA patients are diagnosed at late stages, leading to limited therapeutic effects and poor clinical outcomes [4,5]. Currently, several serum biomarkers are applied for early detection and monitoring of CCA, including CEA, CA19-9, ALP, MUC5AC, and CA-S121.…”

Section: Introductionmentioning

confidence: 99%

Per1 has the capacity to serve as a diagnostic biomarker for cholangiocarcinoma patient

Wang¹,

Li²,

Zheng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Period 1 (Per1) had been reported to be involved in the tumorigenesis and progression of human cancers. However, the clinical significance of Per1 in cholangiocarcinoma (CCA) was unclear. The purpose of this study was to explore the diagnostic value of serum Per1 in CCA patients. Methods Serum levels of Per1 in CCA patients and healthy individuals were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to evaluate the relationship between Per1 expression and clinical characteristics of patients. The diagnostic value of Per1 in CCA was estimated by establishing a receiver operating characteristic (ROC) curve. Results Serum Per1 level was significantly down-regulated in CCA patients compared to that in healthy controls (P < 0.001). Moreover, the decreased expression of Per1 was closely associated with poor histological differentiation (P = 0.040), advanced TNM stage (P = 0.035) and positive lymph node metastasis (P = 0.007). ROC curve indicated that the area under the curve (AUC) was 0.863 with a sensitivity of 88.1% and a specificity of 72.1%, revealing the high diagnostic value of serum Per1 in CCA. Conclusions Per1 is down-regulated in CCA and negatively correlated with tumor progression. Serum Per1 may be a potential biomarker for early screening of CCA.

show abstract

Plasma Peptidome as a Source of Biomarkers for Diagnosis of Cholangiocarcinoma

Cited by 3 publications

References 23 publications

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma

Per1 has the capacity to serve as a diagnostic biomarker for cholangiocarcinoma patient

Contact Info

Product

Resources

About